Bernabei_edit.qxp 30/6/08 02:32 Page 27
Clinical Benefits Associated with a Transdermal Patch for Dementia
prospective study, Arch Neurol, 2003;60(3):387–92. applications, Urology, 2006;67(4):657–64. contraceptive patch vs an oral contraceptive: a randomized
7. Small G, Dubois B, A review of compliance to treatment in 19. Mercier F, Lefevre G, Huang HL, et al., Rivastigmine exposure controlled trial, JAMA, 2001;285(18):2347–54.
Alzheimer’s disease: potential benefits of a transdermal patch, provided by a transdermal patch versus capsules, Curr Med Res 31. Brown RE, Kendall MJ, Halpern MT, Cost analysis of once-daily
Curr Med Res Opin, 2007;23(11):2705–13. Opin, 2007;23:3199–3204. ISMN versus twice-daily ISMN or transdermal patch for nitrate
8. Singh G, Thomas SK, Arcona S, et al., Treatment persistency 20. Frölich L, A review of the first transdermal treatment for prophylaxis, J Clin Pharm Ther, 1997;22(1):67–76.
with rivastigmine and donepezil in a large state medicaid Alzheimer’s disease – the rivastigmine patch, European 32. Burris JF, Papademetriou V, Wallin JD, et al., Therapeutic
program, J Am Geriatr Soc, 2005;53(7):1269–70. Psychiatric Review, 2008;1:33–35. adherence in the elderly: transdermal clonidine compared to
9. Mauskopf JA, Paramore C, Lee WC, Snyder EH, Drug 21. Cummings J, Winblad B, A rivastigmine patch for the treatment oral verapamil for hypertension, Am J Med, 1991;91(1A):
persistency patterns for patients treated with rivastmigine or of Alzheimer’s disease and Parkinson’s disease dementia, Expert 22S–8S.
donepezil in usual care settings, J Manag Care Pharm, 2005; Rev Neurother, 2007;7(11):1457–63. 33. Bodkin JA, Amsterdam JD, Transdermal selegiline in major
11(3):231–9. 22. Winblad B, Cummings J, Andreasen N, et al., A six-month depression: a double-blind, placebo-controlled, parallel-group
10. Roe CM, Anderson MJ, Spivack B, How many patients complete double-blind, randomized, placebo-controlled study of a study in outpatients, Am J Psychiatry, 2002;159(11):1869–75.
an adequate trial of donepezil?, Alzheimer Dis Assoc Disord, transdermal patch in Alzheimer’s disease – rivastigmine patch 34. Alzheimer’s Association and the National Alliance for
2002;16(1):49–51. versus capsule, Int J Geriatr Psychiatry, 2007;22(5):456–67. Caregiving. Caring for Persons with Alzheimer’s: 2004 National
11. Small GW, Kaufer D, Mendiondo MS, et al., Cognitive 23. Corey-Bloom J, Anand R, Veach J, A randomized trial Survey: Alzheimer’s Association and the National Alliance for
performance in Alzheimer’s disease patients receiving evaluating the efficacy and safety of ENA 713 (rivastigmine Caregiving, 2004.
rivastigmine for up to 5 years, Int J Clin Pract, 2005;59(4): tartrate), a new acetylcholinesterase inhibitor, in patients with 35. Travis SS, Kao HF, Acton GJ, Helping family members manage
473–7. mild to moderately severe Alzheimer’s disease, Int J Geriatr medication administration hassles, J Psychosoc Nurs Ment Health
12. Harada ASM, Vanderplas AM, The effect of adherence to Psychopharmacol, 1998;1:55–65. Serv, 2005;43(11):13–15.
Alzheimer’s disease treatment on healthcare costs in managed 24. Schneider LS, Anand R, Farlow MR, Systematic review of the 36. Slattum PW, Johnson MA, Care-giver burden in Alzheimer’s
care. Poster presented at the International Society for efficacy of rivastigmine for patients with Alzheimer’s disease, disease, Consult Pharm, 2004;19(4):352–62.
Pharmacoeconomics and Outcomes Research (ISPOR), Int J Geriatr Psychopharmacol, 1998;1(Suppl. 1):S26–34. 37. Winblad B, Kawata AK, Beusterien KM, et al., Care-giver
Philadelphia, US, 2006. 25. Priano L, Gasco MR, Mauro A, Transdermal treatment options preference for rivastigmine patch relative to capsules for
13. McGraw C, Drennan V, Self-administration of medicine and for neurological disorders: impact on the elderly, Drugs Aging, treatment of probable Alzheimer’s disease, Int J Geriatr
older people, Nurs Stand, 2001;15(18):33–6. 2006;23(5):357–75. Psychiatry, 2007;22(5):485–91.
14. Bond WS, Hussar DA, Detection methods and strategies for 26. Woods DL, Craven RF, Whitney J, The effect of therapeutic 38. Blesa R, Ballard C, Orgogozo J-M, et al., Care-giver preference
improving medication compliance, Am J Hosp Pharm, 1991; touch on behavioral symptoms of persons with dementia, Altern for rivastigmine patches versus capsules for the treatment of
48(9):1978–88. Ther Health Med, 2005;11(1):66–74. Alzheimer disease, Neurology, 2007;69(Suppl. 1):S23–8.
15. Jann MW, Shirley KL, Small GW, Clinical pharmacokinetics and 27. Viggo Hansen N, Jorgensen T, Ortenblad L, Massage and touch 39. Brennan A, Nagy B, Brandtmuller A, et al., The cost-utility of
pharmacodynamics of cholinesterase inhibitors, Clin for dementia, Cochrane Database Syst Rev, 2006(4):CD004989. Exelon patch in the management of patients with Alzheimer’s
Pharmacokinet, 2002;41(10):719–39. 28. Sink KM, Covinsky KE, Barnes DE, et al., Care-giver disease in the UK. Poster presented at the International Society
16. Cummings J, Lefevre G, Small G, Appel-Dingemanse S, characteristics are associated with neuropsychiatric symptoms for Pharmacoeconomics and Outcomes Research (ISPOR),
Pharmacokinetic rationale for the rivastigmine patch, Neurology, of dementia, J Am Geriatr Soc, 2006;54(5):796–803. Dublin, Ireland, 2007.
2007;69(4 Suppl. 1):S10–13. 29. Allan L, Hays H, Jensen NH, et al., Randomised crossover trial 40. Nagy B, Brennan A, Brandtmuller A, et al., The cost-utility of
17. Imbimbo BP, Pharmacodynamic-tolerability relationships of of transdermal fentanyl and sustained release oral morphine for the rivastigmine transdermal patch in the management of
cholinesterase inhibitors for Alzheimer’s disease, CNS Drugs, treating chronic non-cancer pain, BMJ, 2001;322(7295): patients with moderate Alzheimer’s disease in the US. Poster
2001;15(5):375–90. 1154–8. presented at the American Association for Geriatric Psychiatry
18. Nitti VW, Sanders S, Staskin DR, et al., Transdermal delivery of 30. Audet MC, Moreau M, Koltun WD, et al., Evaluation of Annual Meeting, Orlando, Florida, 2008.
drugs for urologic applications: basic principles and contraceptive efficacy and cycle control of a transdermal
Social Protection Frameworks for Dementia Sufferers in
Low- and Middle-income Countries
The 10/66 Dementia Research Group – co-ordinated by the Institute of majority live with their children and are supported by them. In
Psychiatry, King’s College London, and funded by the Wellcome Trust – urban Beijing, findings reveal that many older people live alone or
was founded to improve population-based and social research into with their spouse, but pension coverage is good and children are
dementia in low- and middle-income regions. It is conducting available if needed.
prevalence and impact surveys in 15 catchment areas in India, China, • In all regions, primary healthcare services are used surprisingly
Nigeria, Cuba, Dominican Republic, Puerto Rico, Brazil, Venezuela, infrequently, probably because they fail to meet the long-term
Mexico, Peru and Argentina to improve epidemiological knowledge and needs of people with dementia and their care-givers. In the
aid future strategy. Coverage of Eastern and Central Europe is planned absence of any formal social care structures, families and
in the coming months. communities shoulder a considerable burden. ■
Findings So Far
Percentage of Dementia Sufferers without Children for
Support, Selected Regions
Research carried out by 10/66 suggests that dementia prevalence in
low- and middle-income regions may have been underestimated,
even though dementia is a dominant source of dependency and
within 50 miles
care-giver strain. Social protection for sufferers depends on a critical
interaction between income, living arrangements and availability of
children to provide care. %
• In the Dominican Republic, social protection is compromised by
both low pension coverage and a high proportion of older people
having no children living locally.
Cuba Dominican Venezuela China China India India
• In rural China, few older people have pensions, but the large
(urban) (rural) (urban) (rural)
Source: Alzheimer’s Association. For more information see www.alz.co.uk/1066 or email firstname.lastname@example.org
EUROPEAN PSYCHIATRIC REVIEW 27